Correlation Between Regencell Bioscience and Candel Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Regencell Bioscience and Candel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Regencell Bioscience and Candel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Regencell Bioscience Holdings and Candel Therapeutics, you can compare the effects of market volatilities on Regencell Bioscience and Candel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Regencell Bioscience with a short position of Candel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Regencell Bioscience and Candel Therapeutics.

Diversification Opportunities for Regencell Bioscience and Candel Therapeutics

-0.12
  Correlation Coefficient

Good diversification

The 3 months correlation between Regencell and Candel is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding Regencell Bioscience Holdings and Candel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Candel Therapeutics and Regencell Bioscience is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Regencell Bioscience Holdings are associated (or correlated) with Candel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Candel Therapeutics has no effect on the direction of Regencell Bioscience i.e., Regencell Bioscience and Candel Therapeutics go up and down completely randomly.

Pair Corralation between Regencell Bioscience and Candel Therapeutics

Considering the 90-day investment horizon Regencell Bioscience Holdings is expected to generate 5.02 times more return on investment than Candel Therapeutics. However, Regencell Bioscience is 5.02 times more volatile than Candel Therapeutics. It trades about 0.18 of its potential returns per unit of risk. Candel Therapeutics is currently generating about -0.04 per unit of risk. If you would invest  482.00  in Regencell Bioscience Holdings on December 29, 2024 and sell it today you would earn a total of  3,005  from holding Regencell Bioscience Holdings or generate 623.44% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Regencell Bioscience Holdings  vs.  Candel Therapeutics

 Performance 
       Timeline  
Regencell Bioscience 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Regencell Bioscience Holdings are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile technical and fundamental indicators, Regencell Bioscience exhibited solid returns over the last few months and may actually be approaching a breakup point.
Candel Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Candel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Regencell Bioscience and Candel Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Regencell Bioscience and Candel Therapeutics

The main advantage of trading using opposite Regencell Bioscience and Candel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Regencell Bioscience position performs unexpectedly, Candel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will offset losses from the drop in Candel Therapeutics' long position.
The idea behind Regencell Bioscience Holdings and Candel Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Volatility Analysis
Get historical volatility and risk analysis based on latest market data